CP
PCT icon

Castleview Partners’s PureCycle Technologies PCT Stock Holding History

Castleview Partners’s Portfolio PCT Stock Details PCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$53K Buy
+2,250
New +$48.4K 0.02% 404

Other funds holding PCT

SCH
Sylebra Capital (HK) Hong Kong $1.88B AUM 19.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
HHMI
Howard Hughes Medical Institute Chevy Chase, Maryland $445M AUM 42.75% 1-Year Est. Return
ECA
Encompass Capital Advisors New York $2.81B AUM 198.36% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Castleview Partners's PCT Position: Q2 2021 in Review

Castleview Partners opened a new position in PureCycle Technologies (PCT) in Q2 2021: 2,250 shares worth $53K. The stake represents 0.02% of the portfolio and ranks #404 among its holdings.

110 funds tracked by Wall St. Rank hold PCT as of Q2 2021.

  • Castleview Partners held 2,250 shares of PureCycle Technologies worth $53K as of Q2 2021.
  • PureCycle Technologies was a new Castleview Partners position in Q2 2021.
  • PureCycle Technologies made up 0.02% of Castleview Partners's portfolio in Q2 2021, its #404 holding.
  • 110 funds tracked by Wall St. Rank held PureCycle Technologies as of Q2 2021.

Based on Castleview Partners's 13F filing for Q2 2021, filed 17 Aug 2021.